as 10-30-2025 9:37am EST
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | DENVER |
| Market Cap: | 23.0M | IPO Year: | N/A |
| Target Price: | $9.17 | AVG Volume (30 days): | 182.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $2.82 | Next Earning Date: | 11-13-2025 |
| Revenue: | $66,382,000 | Revenue Growth: | 1.84% |
| Revenue Growth (this year): | -14.16% | Revenue Growth (next year): | 29.12% |
AYTU Breaking Stock News: Dive into AYTU Ticker-Specific Updates for Smart Investing
ACCESS Newswire
20 days ago
ACCESS Newswire
a month ago
ACCESS Newswire
4 months ago
Simply Wall St.
5 months ago
ACCESS Newswire
5 months ago
Pharmaceutical Technology
5 months ago
ACCESS Newswire
5 months ago
ACCESS Newswire
5 months ago
The information presented on this page, "AYTU Aytu BioPharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.